Next-generation obesity drugs
Retatrutide (triple agonist), CagriSema, amycretin, MariTide, petrelintide, Pfizer/Metsera MET-097i/MET-233i, mazdutide (approved in China).
7 leading companies in next-generation obesity drugs, one segment of pharma: glp-1 & obesity drugs — Semaglutide, tirzepatide and the next wave: about $132B in 2025 GLP-1 sales, with generics now open in Canada
new market segment · researched 2026-11-14
GLP-1 diabetes drugsWeight-loss (obesity) injectablesOral GLP-1 pillsNext-generation obesity drugsGeneric semaglutideSupply chain, compounding & pharmacy
C
Leading next-generation obesity drugs companies
7 companies, with the scale each source states. Scale is the whole company's unless the row says otherwise.
| Company | Where | What they do | Scale |
|---|---|---|---|
| Amgen AMGN ↗ | Thousand Oaks, United States since 1980 | MariTide (maridebart cafraglutide): a GIPR-antibody/GLP-1 peptide conjugate in investigational development for obesity. | — |
| Roche ROG.SW ↗ | Basel, Switzerland since 1896 | Partner on Zealand Pharma's amylin analog petrelintide (Phase IIb, obesity and type 2 diabetes). | — |
| Zealand Pharma ZEAL.CO ↗ | Søborg, Denmark since 1998 | Peptide biotech developing petrelintide (amylin analog) with Roche. | — |
| Innovent Biologics 1801.HK ↗ | Suzhou, China since 2011 | Co-developer, with Lilly, of mazdutide (GLP-1/glucagon), approved for marketing in China in June 2025. | — |
| Pfizer (Metsera) PFE ↗ | New York, United States since 1849 | Bought Metsera (completed 13 Nov 2025). Gained MET-097i, a weekly/monthly injectable GLP-1 about to enter Phase 3, and MET-233i, a monthly amylin analog. | acquisition enterprise value: 7 USD billions plus CVR up to $20.65/share (2025) ↗ |
| Eli Lilly and Company LLY ↗ | Indianapolis, United States since 1876 | Tirzepatide (Mounjaro, Zepbound), orforglipron pill (Foundayo) and retatrutide in Phase 3. Reached $1T market cap Nov 2025. | revenue: 65.179 USD billions (total company) (2025) ↗ |
| Novo Nordisk NOVO-B.CO / NVO ↗ | Bagsværd, Denmark since 1923 | Semaglutide (Ozempic, Wegovy, Rybelsus, oral Wegovy) and liraglutide. CagriSema and amycretin in development. | revenue: 309.1 DKK billions (total company) (2025) ↗ |
M
The pharma: glp-1 & obesity drugs market
The whole market this segment sits in.
global revenue · world132
↗USD billions (GLP-1 therapies, all indications) · 2025
Growth, segments, risks and every company in pharma: glp-1 & obesity drugs →
Quick answers
- What are next-generation obesity drugs?
- Retatrutide (triple agonist), CagriSema, amycretin, MariTide, petrelintide, Pfizer/Metsera MET-097i/MET-233i, mazdutide (approved in China). They are one segment of the pharma: glp-1 & obesity drugs market.
- Who are the leading next-generation obesity drugs companies?
- Amgen (United States), Roche (Switzerland), Zealand Pharma (Denmark), Innovent Biologics (China), Pfizer (Metsera) (United States), Eli Lilly and Company (United States), Novo Nordisk (Denmark).
- Which next-generation obesity drugs companies are publicly traded?
- Amgen (AMGN), Roche (ROG.SW), Zealand Pharma (ZEAL.CO), Innovent Biologics (1801.HK), Pfizer (Metsera) (PFE), Eli Lilly and Company (LLY), Novo Nordisk (NOVO-B.CO / NVO).
- How big is the pharma: glp-1 & obesity drugs market?
- For the whole pharma: glp-1 & obesity drugs market, not this segment alone: global revenue (world) 132 USD billions (GLP-1 therapies, all indications), 2025 — Managed Healthcare Executive.